<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778167</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00286</org_study_id>
    <secondary_id>NCI-2009-00286</secondary_id>
    <secondary_id>CDR0000617094</secondary_id>
    <secondary_id>UCHSC-08-0044</secondary_id>
    <secondary_id>COMIRB 08-0044</secondary_id>
    <secondary_id>8148</secondary_id>
    <secondary_id>P30CA046934</secondary_id>
    <secondary_id>N01CM62209</secondary_id>
    <secondary_id>R21CA135595</secondary_id>
    <nct_id>NCT00778167</nct_id>
  </id_info>
  <brief_title>Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/Randomized Phase II Study of the Anti-IGF-1R Monoclonal Antibody IMC-A12 in Combination With Erlotinib Compared With Erlotinib Alone in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase I/II trial is studying the side effects and best dose of cixutumumab&#xD;
      and to see how well erlotinib hydrochloride works when given together with or without&#xD;
      cixutumumab in treating patients with stage III or stage IV non-small cell lung cancer.&#xD;
      Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth in&#xD;
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor&#xD;
      cells and help kill them or carry tumor-killing substances to them. It is not yet known&#xD;
      whether erlotinib hydrochloride is more effective when given together with or without&#xD;
      cixutumumab in treating non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine a tolerable dose of IMC-A12 (cixutumumab) in combination with erlotinib&#xD;
      (erlotinib hydrochloride) in the target NSCLC population to be administered in the randomized&#xD;
      phase II study section.&#xD;
&#xD;
      II. To determine the difference in PFS between the anti-IGF-1R monoclonal antibody IMC-A12 in&#xD;
      combination with erlotinib compared to erlotinib alone in the target NSCLC population.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the safety, tolerability, and adverse event profile of IMC-A12 in combination&#xD;
      with erlotinib in patients with advanced non-small cell lung cancer.&#xD;
&#xD;
      II. To describe preliminary evidence of clinical activity of the combination of IMC-A12 and&#xD;
      erlotinib.&#xD;
&#xD;
      III. To determine the difference in overall response rate (ORR) between the two treatment&#xD;
      arms.&#xD;
&#xD;
      IV. To determine the response duration in patients who achieve an objective response in&#xD;
      either study arm.&#xD;
&#xD;
      V. To describe the response rate, time to disease progression, and response duration in the&#xD;
      population who cross over to the combination arm after disease progression with single agent&#xD;
      erlotinib therapy.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To explore the prognostic/predictive significance of the immunohistochemical, mutational,&#xD;
      and cytogenetic profiles from archived tumor tissue of key elements of the EGFR, IGF-1R and&#xD;
      other relevant signaling pathways in relationship to clinical benefit from treated&#xD;
      individuals in both Part A and Part B sections of the study.&#xD;
&#xD;
      II. To explore the prognostic/predictive significance of serum circulating markers (ligands&#xD;
      and binding proteins) and serum proteomic profiles pre-treatment and at progression in both&#xD;
      Part A and Part B sections of the study.&#xD;
&#xD;
      III. To explore the impact of SNPs in germline and tumor derived DNA on toxicity and&#xD;
      anti-cancer activity within both Part A and Part B sections of the study.&#xD;
&#xD;
      IV. To explore the impact of SNPs in germline DNA on erlotinib pharmacokinetics within both&#xD;
      Part A and Part B sections of the study.&#xD;
&#xD;
      OUTLINE: This is a multicenter study that includes a single-arm safety evaluation phase I&#xD;
      followed by a randomized phase II study.&#xD;
&#xD;
      Initially, patients are enrolled in the safety evaluation phase. If ≤ 2 of 10 patients&#xD;
      experience a dose-limiting toxicity, then the study may proceed to the randomized phase.&#xD;
      Safety evaluation phase I: Patients receive cixutumumab intravenously (IV) over 1 hour on&#xD;
      days 1, 8, 15, and 22 and erlotinib hydrochloride orally (PO) once daily on days 1-28.&#xD;
      Courses repeat every 28 days until disease progression or unacceptable toxicity.&#xD;
&#xD;
      Randomized phase II: Patients are stratified according to performance status, history of&#xD;
      smoking (never vs ex vs current), stage of disease (IIIA vs IIIB without malignant effusion&#xD;
      vs IIIB with malignant effusion vs IV), EGFR mutation (present vs absent vs not known), and&#xD;
      disease histology (squamous vs non-squamous). Patients are randomized to 1 of 2 treatment&#xD;
      arms.&#xD;
&#xD;
      ARM 1: Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with&#xD;
      documented disease progression may cross over and receive treatment on arm II.&#xD;
&#xD;
      ARM II: Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1&#xD;
      hour on days 1, 8, and 15. Patients receive treatment in both arms as in the safety&#xD;
      evaluation portion. Courses repeat every 21 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Archived tissue and blood samples are collected periodically for pharmacokinetic analysis of&#xD;
      erlotinib hydrochloride; pharmacogenomic analysis of EGRF, IGF1R, and CYP3A4/5 mutations; IHC&#xD;
      and FISH analysis of IGF1R, EGFR, cMET, ras, Akt1, and EMT; proteomic analysis of serum&#xD;
      ligand/binding proteins (i.e., IGF1, IGF2, IGFBPs, EGF, HRG, and TGF-α) using matrix-assisted&#xD;
      laser desorption/ionization time of flight mass spectrometry (MALDI-TOF); mutational status&#xD;
      analysis of EGFR and related pathway proteins; and RT-PCR analysis.&#xD;
&#xD;
      After completion of study therapy, patients are followed for 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of IMC-A12 in Combination With Erlotinib Hydrochloride as Graded by Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0 (DLTs During Cycle One)</measure>
    <time_frame>From time of first dose up to 28 days</time_frame>
    <description>Patients were evaluable for cohort dose escalation/de-escalation decision making either if they experienced DLTs in cycle 1 or if they had completed 24 of the planned 28 days (85%) dosing of erlotinib and three of the four planned days of weekly dosing of cixutumumab (75%) in cycle 1 in cohorts 1 and 2 in the absence of DLTs. In cohort 3, patients were evaluable for tolerability if they had completed 18 days (85%) dosing of erlotinib and had received the planned day 1 dose of cixutumumab.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (Enzyme inhibitor therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO once daily on days 1-21. Patients with documented disease progression may cross over and receive treatment on arm II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (Enzyme inhibitor and monoclonal antibody therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive erlotinib hydrochloride PO as in arm I and cixutumumab IV over 1 hour on days 1, 8, and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cixutumumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (Enzyme inhibitor and monoclonal antibody therapy)</arm_group_label>
    <other_name>anti-IGF-1R recombinant monoclonal antibody IMC-A12</other_name>
    <other_name>IMC-A12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (Enzyme inhibitor therapy)</arm_group_label>
    <arm_group_label>Arm II (Enzyme inhibitor and monoclonal antibody therapy)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (Enzyme inhibitor therapy)</arm_group_label>
    <arm_group_label>Arm II (Enzyme inhibitor and monoclonal antibody therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IIIA, IIIB, or IV disease&#xD;
&#xD;
               -  Mixed histology permitted provided small-cell elements are not present&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Must have failed ≥ 1 platinum-containing chemotherapy regimen&#xD;
&#xD;
          -  CNS metastases are eligible if received prior radiotherapy to site(s) of CNS&#xD;
             metastatic disease, or have had definitive resection of CNS metastatic disease and&#xD;
             have no overt evidence of neurological deficits, are not requiring anti-epileptics,&#xD;
             remain asymptomatic, and have been off steroids for ≥ 8 weeks&#xD;
&#xD;
          -  ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/mm³&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Platelets ≥ 100,000/mm³&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Fasting serum glucose &lt; 120 mg/dL OR normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to anti-IGF-1R recombinant monoclonal antibody IMC-A122 or&#xD;
             erlotinib hydrochloride&#xD;
&#xD;
          -  No poorly controlled diabetes mellitus&#xD;
&#xD;
               -  Patients with a history of diabetes mellitus are eligible, provided their blood&#xD;
                  glucose is within normal range at screening and they are on a stable dietary or&#xD;
                  therapeutic regimen for this condition&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No inability to take oral medications or, in the investigator's opinion,&#xD;
             gastrointestinal conditions or abnormalities likely to influence the absorption of&#xD;
             oral medications&#xD;
&#xD;
          -  No prior or concurrent exposure to other EGFR or IGFR inhibitors&#xD;
&#xD;
          -  Recovered from all prior therapy with acute effects resolved to ≤ grade 1&#xD;
&#xD;
          -  At least 28 days since prior anticancer or investigational agent (within predicted 5&#xD;
             half-lives of agent)&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy to target lesions and documented disease&#xD;
             progression at these sites&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy to non-target lesions&#xD;
&#xD;
          -  More than 4 months since prior major surgery or hormonal therapy (other than&#xD;
             replacement)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Camidge</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <results_first_submitted>January 15, 2013</results_first_submitted>
  <results_first_submitted_qc>March 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 23, 2013</results_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between December 2008 and October 2010, 18 patients were enrolled across cohorts 1 to 3.</recruitment_details>
      <pre_assignment_details>Phase I of the study, determining a tolerable dose of IMC-A12 in combination with erlotinib, was completed. Because of concerns about the achievable dose intensity at the maximum tolerated dose, a randomized phase II study that would have involved Arm I in comparing full-dose erlotinib with the IMC-A12 in combination with erlotinib was cancelled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1</title>
          <description>Cohort 1: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 6 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2</title>
          <description>Cohort 2: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 5 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3</title>
          <description>Cohort 3: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 15 mg/kg IV in 21-day cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1</title>
          <description>Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 6 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2</title>
          <description>Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 5 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3</title>
          <description>Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 15 mg/kg IV in 21-day cycles.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=48 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 48 and 77 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=77 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of IMC-A12 in Combination With Erlotinib Hydrochloride as Graded by Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0 (DLTs During Cycle One)</title>
        <description>Patients were evaluable for cohort dose escalation/de-escalation decision making either if they experienced DLTs in cycle 1 or if they had completed 24 of the planned 28 days (85%) dosing of erlotinib and three of the four planned days of weekly dosing of cixutumumab (75%) in cycle 1 in cohorts 1 and 2 in the absence of DLTs. In cohort 3, patients were evaluable for tolerability if they had completed 18 days (85%) dosing of erlotinib and had received the planned day 1 dose of cixutumumab.</description>
        <time_frame>From time of first dose up to 28 days</time_frame>
        <population>Patients were evaluated with history, physical examination, vital signs, and blood tests weekly through cycle 1 and on day 1 of each subsequent cycle. Incidence and severity of AEs were collected at each study visit and graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1</title>
            <description>Cohort 1: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 6 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2</title>
            <description>Cohort 2: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 5 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3</title>
            <description>Cohort 3: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 15 mg/kg IV in 21-day cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of IMC-A12 in Combination With Erlotinib Hydrochloride as Graded by Common Terminology Criteria for Adverse Event (CTCAE) Version 3.0 (DLTs During Cycle One)</title>
          <description>Patients were evaluable for cohort dose escalation/de-escalation decision making either if they experienced DLTs in cycle 1 or if they had completed 24 of the planned 28 days (85%) dosing of erlotinib and three of the four planned days of weekly dosing of cixutumumab (75%) in cycle 1 in cohorts 1 and 2 in the absence of DLTs. In cohort 3, patients were evaluable for tolerability if they had completed 18 days (85%) dosing of erlotinib and had received the planned day 1 dose of cixutumumab.</description>
          <population>Patients were evaluated with history, physical examination, vital signs, and blood tests weekly through cycle 1 and on day 1 of each subsequent cycle. Incidence and severity of AEs were collected at each study visit and graded according to National Cancer Institute Common Toxicity Criteria for Adverse Events version 3.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weekly through cycle 1 and on day 1 of each subsequent cycle</time_frame>
      <desc>Patients were evaluated with history, physical examination, vital signs, and blood tests weekly through cycle 1 and on day 1 of each subsequent cycle. Incidence and severity of AEs were collected at each study visit</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1</title>
          <description>Cohort 1: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 6 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2</title>
          <description>Cohort 2: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 5 mg/kg IV on days 1, 8, 15, and 22 in 28-day cycles.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3</title>
          <description>Cohort 3: Patients received oral erlotinib hydrochloride 150 mg once daily with cixutumumab 15 mg/kg IV in 21-day cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Taste alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acneiform rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Phase I of the study was completed but because of concerns about the achievable dose intensity at the maximum tolerated dose (MTD), the expansion into a randomized phase II study comparing full-dose erlotinib with the combination was cancelled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David R. Camidge</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>720-848-0449</phone>
      <email>ross.camidge@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

